Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology2018Vol. 36(28), pp. 2845–2853
Citations Over TimeTop 1% of 2018 papers
David M. Kurtz, Florian Scherer, Michael C. Jin, Joanne Soo, Alexander Craig, Mohammad Shahrokh Esfahani, Jacob J. Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron M. Newman, Ulrich Dührsen, Andreas Hüttmann, Michel Meignan, Olivier Casasnovas, Jason R. Westin, Mark Roschewski, Wyndham H. Wilson, Gianluca Gaïdano, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh
Abstract
Pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in aggressive lymphomas. These risk factors could potentially guide future personalized risk-directed approaches.
Related Papers
- → MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.(2016)9 cited
- → Prognostic Value of the t(14;18)(q32;q21) in Patients With Diffuse Large B-Cell Lymphoma(2010)2 cited
- → Prognostic Value of the t(14;18)(q32;q21) in Patients With Diffuse Large B-Cell Lymphoma(2010)1 cited
- → Improving the Prognostic Index for Diffuse Large B-Cell Lymphoma(2014)
- → Lower Prognostic Performance of the International Metabolic Prognostic Index Compared to the Conventional IPI and NCCN-IPI in a Real-World Cohort of Diffuse Large B-Cell Lymphoma(2023)